COMPARISON OF DIFFERENT SKIN CARE REGIMENS FOR PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS IN ADDITION TO SYSTEMIC TREATMENT

Moderate to severe Atopic Dermatitis (AD) can be successfully managed by systemic treatment Cyclosporin A, biologics (dupilumab, tralokinumab) or Janus kinase (JAK) inhibitors. This allows a significant improvement in patient’s quality of life. Current guidelines for management of AD recommend emollients and gentle cleansers for all patients to improve the epidermal barrier and provide anti-irritant and anti-pruritic effects. Various emollients have been developed and used in skincare products for dry and sensitive skin. A skincare routine, an Emollient + and a dedicated syndet, was designed not only to improve the physical skin barrier, but also to rebalance the skin microbiome which has a key role in AD.